http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Novocure to Report Second Quarter 2022 Financial Results
-
Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer
-
Zai Lab Limited (ZLAB) and Novocure (NVCR) Report Phase 2 Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint
-
Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
-
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
-
Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
-
Novocure (NVCR) Announces Clinical Collaboration with MSD on Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA in Newly Diagnosed Glioblastoma
-
Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma
-
Novocure Reports First Quarter 2022 Financial Results
-
Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu
-
Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields
-
Novocure to Report First Quarter 2022 Financial Results
-
Novocure (NVCR) Reports Updated 2-THE-TOP Data Suggesting Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control
-
Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial
-
Novocure (NVCR) Recommended to Continue the Phase 3 Pivotal INNOVATE-3 Study
-
Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer
-
Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation
-
Novocure’s General Counsel Resigns After 10 Years of Service
-
New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response
-
Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
-
Novocure (NVCR) Reports Prelim. Q4 Results
-
Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update
-
Novocure to Participate in the 40th Annual J.P. Morgan Healthcare Conference
-
Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New Hampshire
-
Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
-
Novocure to Participate in Two Upcoming Investor Conferences
-
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer
-
Novocure (NVCR) Reports Positive Top-Line Results from 2-THE-TOP Phase 2 Trial
-
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma
-
Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting
-
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer
-
Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update
-
Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting
-
Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
-
Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
-
Novocure to Report Third Quarter 2021 Financial Results
-
Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
-
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer
-
Novocure (NVCR) Announces FDA Grants Breakthrough Device Designation to NovoTTF-200T System for Advanced Liver Cancer
-
FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer
-
Novocure to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
-
Novocure Appoints Bill Burke as Chief Human Resources Officer
-
Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update
-
Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
-
Novocure to Report Second Quarter 2021 Financial Results
-
Novocure (NVCR) Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer
-
Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer
-
Novocure Initiates Usability Study for Flexible Torso Array
-
Novocure (NVCR) Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile Therapy in Recurrent Glioblastoma
-
Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent Glioblastoma
